Embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited

Key Points from the Announcement

• Acquisition Deal: Embecta Corp. (Nasdaq: EMBC) has entered into a definitive agreement to acquire Owen Mumford Holdings Limited, a UK-based privately held innovator and manufacturer of drug-delivery medical devices.
• Transaction Value: The deal is valued at up to £150 million. This includes an upfront cash payment of £100 million at closing (subject to customary adjustments) and up to £50 million in performance-based payments tied to net sales of the Aidaptus® auto-injector platform over the three years post-closing.
• Board Approval and Expected Closing: The Embecta Board of Directors unanimously approved the transaction, which is expected to close in Embecta’s fiscal third quarter of 2026, pending regulatory approvals and customary closing conditions.
• Strategic Rationale: The acquisition positions Embecta to expand from diabetes care technology into the broader, fast-growing market for drug-delivery devices supporting generic and branded therapies. It is a key step in transforming Embecta into a broad-based medical supplies company.

Details of the Acquisition

• Owen Mumford Overview: Founded in 1952 and headquartered in Oxfordshire, UK, Owen Mumford is recognized for its innovative drug delivery platforms and medical device technologies. The company serves leading pharmaceutical, biotech, and healthcare organizations worldwide.
• Product Portfolio: Owen Mumford is known for pioneering the first plastic autoinjector and continues to expand its offering, with a focus on the next-generation Aidaptus® auto-injector platform, as well as devices for point-of-care testing, self-injection, and pelvic health.
• Geographic Synergy: Owen Mumford generated about 80% of its fiscal 2025 revenue in the UK and US, presenting significant opportunity for Embecta to leverage its global commercial infrastructure for broader distribution.
• Financial Profile: In fiscal 2025, Owen Mumford reported net revenue of £69.4 million.

Strategic and Financial Impact for Shareholders

• Diversification and Growth: The acquisition adds a differentiated drug-delivery platform and strengthens Embecta’s intellectual property portfolio. The Aidaptus® platform streamlines manufacturing and supply chain complexity, offering a scalable solution for pharmaceutical partners across multiple therapeutic areas such as obesity, diabetes, autoimmune diseases, and anaphylaxis.
• Operational Efficiencies: The combination of Owen Mumford’s device design and manufacturing expertise with Embecta’s large-scale manufacturing capabilities is expected to create operational efficiencies and expand future product capacity.
• Revenue Contribution: Embecta expects the acquisition to contribute to revenue growth from fiscal year 2027 onwards.
• Profitability and Earnings Impact: The transaction is expected to be immaterial to adjusted operating income in fiscal 2027, accretive thereafter, dilutive to adjusted net income in 2027, immaterial in 2028, and accretive thereafter. By year four, it is projected to generate a high-single-digit return on invested capital, with increasing contributions thereafter.
• Financing: The purchase price will be funded through borrowings under Embecta’s revolving credit facility. The company remains committed to debt reduction and maintaining financial flexibility long-term.

Other Important Information for Investors

• Advisors: J.P. Morgan Securities LLC is acting as financial advisor and A&O Shearman LLP as legal counsel to Embecta. Forvis Mazars LLP and Mills & Reeve LLP are advising Owen Mumford.
• Further Information: Embecta will discuss this acquisition in greater detail during its fiscal second quarter 2026 earnings conference call, scheduled for May 5, 2026.
• Forward-Looking Statements: The press release contains forward-looking statements regarding the acquisition and Embecta’s strategic direction. Actual results may differ materially due to various risks and uncertainties, as described in the company’s filings with the SEC.

Potential Impact on Share Price

This acquisition is a significant move by Embecta, positioning the company for long-term growth, diversification, and increased market presence in the lucrative drug-delivery device sector. The transition from a pure-play diabetes care technology provider to a broader medical supplies company could materially affect future revenue and profitability, offering potential upside for shareholders. However, investors should also consider near-term earnings dilution and integration risks. The performance-based structure of the deal aligns Owen Mumford’s future success with Embecta’s interests, which could drive further value if key milestones are met.

Contact Information

• Media: Christian Glazar, Sr. Director, Corporate Communications, 908-821-6922
• Investors: Pravesh Khandelwal, VP, Head of Investor Relations, 551-264-6547

About Embecta

Embecta is a global company building on its 100-year legacy in insulin delivery, now expanding into a broad-based medical supplies company. For more information, visit embecta.com.

About Owen Mumford

Owen Mumford is a family-owned medical technology company with over 70 years of innovation in healthcare device development, particularly in drug delivery technologies and chronic care medical devices.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review all company filings and conduct their own due diligence before making any investment decisions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated.

View Embecta Corp. Historical chart here